Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

A hormone expert has explained why some people’s sex drive goes ‘through the roof’ while using Mounjaro. Use of the drug for ...

With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...